Brooks P M, McCredie M, Prowse M, Podgorski M, Forrest M, Munro I, Boutagy J, Pei-Ling L
Pharmatherapeutica. 1986;4(10):665-72.
The pharmacokinetics of isoxicam, a new non-steroidal anti-inflammatory drug, were studied in 20 osteoarthritis patients with varying degrees of renal insufficiency. A wide variation in pharmacokinetic parameters was seen between individuals but there was no suggestion that renal function influenced pharmacokinetics. Steady state plasma isoxicam concentrations varied from 20 micrograms/ml to 130 micrograms/ml, while the plasma half-life varied from 23 hours to 58 hours. Despite a reduction in urinary prostaglandin E2 excretion, isoxicam administration did not alter renal function over a 4-week period.
对20名肾功能不全程度各异的骨关节炎患者，研究了一种新型非甾体抗炎药异恶酰胺的药代动力学。个体间药代动力学参数差异很大，但没有迹象表明肾功能会影响药代动力学。稳态血浆异恶酰胺浓度在20微克/毫升至130微克/毫升之间变化，而血浆半衰期在23小时至58小时之间变化。尽管尿前列腺素E2排泄减少，但在4周期间，服用异恶酰胺并未改变肾功能。
